Profile data is unavailable for this security.
About the company
Eton Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing treatments for rare diseases. The Company has five commercial rare disease products: ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector. ALKINDI SPRINKLE is a granule hydrocortisone formulation designed to help provide accurate dosing for newborns and children with adrenal insufficiency. PKU GOLIKE is a next generation medical formula product engineered with the patent protected, pharmaceutical grade Physiomimic technology for the dietary management of phenylketonuria (PKU) under medical supervision. Carglumic Acid is used for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is developed for the treatment of homocystinuria.
- Revenue in USD (TTM)31.64m
- Net income in USD-936.00k
- Incorporated2017
- Employees30.00
- LocationEton Pharmaceuticals Inc21925 W Field Pkwy Ste 235DEER PARK 60010-7278United StatesUSA
- Phone+1 (847) 787-7361
- Websitehttps://etonpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aileron Therapeutics Inc | 0.00 | -15.73m | 84.86m | 15.00 | -- | 3.55 | -- | -- | -3.39 | -3.39 | 0.00 | 20.12 | 0.00 | -- | -- | 0.00 | -24.58 | -65.99 | -26.17 | -75.37 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.43 | -- | -- | -- |
| Aclaris Therapeutics Inc | 31.25m | -88.48m | 85.11m | 91.00 | -- | 0.5413 | -- | 2.72 | -1.27 | -1.27 | 0.4477 | 2.22 | 0.1383 | -- | 79.92 | 343,395.60 | -39.15 | -47.29 | -44.34 | -53.87 | 42.14 | 44.00 | -283.15 | -549.18 | -- | -- | 0.00 | -- | 5.03 | 38.41 | -1.81 | -- | -0.703 | -- |
| Curis Inc | 10.02m | -47.41m | 85.29m | 48.00 | -- | 4.34 | -- | 8.51 | -9.02 | -9.02 | 1.89 | 3.34 | 0.1077 | -- | 3.47 | 208,812.50 | -50.95 | -37.25 | -58.32 | -41.12 | 97.88 | 96.05 | -473.04 | -409.44 | -- | -- | 0.00 | -- | -1.37 | -0.7891 | 16.34 | -- | -- | -- |
| Gritstone bio Inc | 16.35m | -138.49m | 86.15m | 231.00 | -- | 1.53 | -- | 5.27 | -1.55 | -1.55 | 0.1827 | 0.5313 | 0.0781 | -- | 36.53 | 70,761.91 | -66.18 | -48.08 | -77.72 | -55.18 | -- | -- | -847.24 | -573.71 | -- | -- | 0.4364 | -- | -18.05 | 68.96 | -15.71 | -- | -4.19 | -- |
| BioXcel Therapeutics Inc | 1.38m | -179.05m | 87.94m | 74.00 | -- | -- | -- | 63.72 | -6.16 | -6.16 | 0.0474 | -1.89 | 0.0099 | 0.6343 | 8.65 | 18,648.65 | -128.10 | -74.57 | -163.23 | -84.06 | 8.62 | -- | -12,974.86 | -32,300.74 | 2.57 | -21.87 | 2.28 | -- | 268.00 | -- | -8.02 | -- | -43.26 | -- |
| Zhong Yuan Bio-Technology Holdings Ltd | 2.49m | 232.02k | 88.40m | 35.00 | 392.16 | 349.14 | -- | 35.45 | 0.0128 | -0.0176 | 0.1395 | 0.0143 | 0.8583 | -1.61 | 3.25 | 71,253.43 | 6.49 | -- | 19.10 | -- | 106.30 | -- | 7.57 | -- | 0.8309 | 2.53 | 0.8593 | -- | -28.60 | -- | -148.37 | -- | -- | -- |
| Eton Pharmaceuticals Inc | 31.64m | -936.00k | 88.62m | 30.00 | -- | 5.73 | -- | 2.80 | -0.0389 | -0.0389 | 1.23 | 0.6025 | 1.11 | 14.42 | 12.02 | 1,054,733.00 | -3.30 | -46.22 | -5.49 | -58.20 | 66.56 | 72.16 | -2.96 | -76.86 | 1.60 | -- | 0.258 | -- | 48.90 | -- | 89.62 | -- | 26.85 | -- |
| Abeona Therapeutics Inc | 3.50m | -54.19m | 89.18m | 84.00 | -- | 5.83 | -- | 25.48 | -2.59 | -2.59 | 0.1639 | 0.559 | 0.0546 | -- | 2.66 | 41,666.67 | -84.53 | -53.22 | -101.27 | -65.81 | -- | -- | -1,548.23 | -1,894.25 | -- | -- | 0.00 | -- | 147.52 | 3.14 | -24.63 | -- | -55.74 | -- |
| Allakos Inc | 0.00 | -185.70m | 89.63m | 131.00 | -- | 0.5302 | -- | -- | -2.14 | -2.14 | 0.00 | 1.92 | 0.00 | -- | -- | 0.00 | -58.95 | -42.71 | -65.92 | -45.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 41.96 | -- | -38.89 | -- |
| PMV Pharmaceuticals Inc | 0.00 | -68.96m | 90.03m | 63.00 | -- | 0.3989 | -- | -- | -1.44 | -1.44 | 0.00 | 4.39 | 0.00 | -- | -- | 0.00 | -26.40 | -21.16 | -27.72 | -21.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.94 | -- | 16.31 | -- |
| Allovir Inc | 0.00 | -190.42m | 90.92m | 112.00 | -- | -- | -- | -- | -1.83 | -1.83 | 0.00 | -- | -- | -- | -- | 0.00 | -- | -52.85 | -- | -57.72 | -- | -- | -- | -378,613.90 | -- | -- | -- | -- | -- | -- | -12.87 | -- | -- | -- |
| Genelux Corp | 170.00k | -28.30m | 91.34m | 23.00 | -- | 4.60 | -- | 537.31 | -1.22 | -1.22 | 0.007 | 0.7389 | 0.0102 | -- | -- | 7,391.30 | -169.32 | -- | -- | -- | -- | -- | -16,645.29 | -- | -- | -6.48 | 0.00 | -- | -98.46 | -- | -443.44 | -- | -- | -- |
| Angion Biomedica Corp | 0.00 | -35.19m | 92.02m | 32.00 | -- | 7.59 | -- | -- | -8.81 | -8.81 | 0.00 | 1.18 | 0.00 | -- | -- | 0.00 | -88.05 | -105.91 | -110.32 | -331.69 | -- | -- | -- | -712.81 | -- | -700.88 | 0.00 | -- | -100.00 | -- | 9.31 | -- | -- | -- |
| IO Biotech Inc | 0.00 | -86.08m | 93.55m | 68.00 | -- | 0.7025 | -- | -- | -2.15 | -2.15 | 0.00 | 2.02 | 0.00 | -- | -- | 0.00 | -56.91 | -- | -62.35 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.47 | -- | -- | -- |
Data as of Apr 26 2024. Currency figures normalised to Eton Pharmaceuticals Inc's reporting currency: US Dollar USD
23.50%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Opaleye Management, Inc.as of 31 Dec 2023 | 2.53m | 9.85% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 1.02m | 3.97% |
| Westside Investment Management LLCas of 31 Mar 2024 | 573.96k | 2.23% |
| Acuitas Investments LLCas of 31 Dec 2023 | 492.05k | 1.92% |
| Paradigm Capital Management, Inc.as of 31 Dec 2023 | 300.00k | 1.17% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 281.01k | 1.09% |
| Bridgeway Capital Management LLCas of 31 Dec 2023 | 253.36k | 0.99% |
| Geode Capital Management LLCas of 31 Dec 2023 | 227.26k | 0.89% |
| Parkman Healthcare Partners LLCas of 31 Dec 2023 | 199.17k | 0.78% |
| Columbia Management Investment Advisers LLCas of 31 Dec 2023 | 161.93k | 0.63% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
